Tirzepatide

FDA Approved

Weight Management

A dual GIP/GLP-1 receptor agonist that delivers superior weight loss and metabolic improvements compared to single-target therapies.

Administration

Subcutaneous injection

Dosage Range

2.5-15 mg weekly (titrated)

Mechanism of Action

Tirzepatide activates both GIP and GLP-1 receptors, creating a synergistic effect on appetite suppression, insulin secretion, and fat metabolism that exceeds single-receptor agonists.

Clinical Benefits

Superior weight loss (up to 22.5%)

Improved insulin sensitivity

Reduced HbA1c

Cardiovascular benefits

Reduced liver fat

Clinical Evidence

FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity. SURMOUNT trials showed up to 22.5% weight loss at highest dose. SURPASS trials demonstrated superior glycemic control.

Side Effects

Nausea

Diarrhea

Decreased appetite

Vomiting

Constipation

Contraindications

MEN 2 syndrome

Medullary thyroid carcinoma history

Severe GI disease

Pregnancy

Related Peptides in Weight Management

Semaglutide

A GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes significant weight loss with cardiovascular benefits.

AOD-9604

A modified fragment of human growth hormone (hGH 176-191) that stimulates fat metabolism without the growth-promoting effects of full GH.

MOTS-c

A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic function and insulin sensitivity.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.